In:
Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 3753-3753
Abstract:
Chronic lymphocytic leukemia, the most common form of adult leukemia in the Western world, is characterized by a heterogeneous clinical course, with indolent or progressive forms that entail profoundly different approaches to treatment. The biomarkers useful to predict the clinical course of CLL encompass cytogenetic abnormalities, protein expression (ZAP70, CD38) and IGHV mutation status. Among the many molecular features characterizing biological and clinical aspects of CLL patients, deletion of 13q14 and down-regulation of its related microRNAs (miR-15a and miR-16-1) are the most frequent aberrations in CLL. The involvement of the miR-15a and mir-16-1 in CLL has been extensively described by in vivo and in vitro studies and the genomic region encompassing the miR cluster results frequently deleted, but the mechanisms that regulate the expression of these miRs in CLL are still poorly understood. Here we demonstrate that the G to A single nucleotide polymorphism (SNP) rs115069827 prevents the maturation of miR-15a by reducing the binding of the DROSHA complex to the pri-microRNA 15a/16-1. The study of this functional SNP allowed us to discover a novel mechanism of transcription of the miR-15a/16-1 cluster, independent of DLEU2, its host gene. We demonstrate that the genomic region immediately upstream of the miR-15a/16-1, including the SNP, acts as transcriptional activator. The miR-15a/16-1 cluster is transcribed by allele-specific mechanisms: transcription of one allele is driven by the RNA Polymerase II at the DLEU2 promoter, while the other allele is transcribed by a mechanism that involves occupancy of the newly identified transcription activator region by RNA Polymerase III. Interestingly, the latter mechanism is dominant within CLL cells with mono-allelic 13q14 deletion and high expression of ZAP70 (Fisher's exact test p:0.0128) (Table1). Moreover, in our patient cohorts (training set n=28, validation set n=19) there are CLL samples with cells carrying 13q14 deletions that did not encompass the miR-15a/16-1 locus. Almost all of these show high expression of ZAP70 (Fisher's exact test training set p:0.0055; validation set p:0.0374) and primiR regulation by RPIII, in the presence of both alleles of miR-15a/16-1. By CNV analysis of a more telomeric region (∼30 kb, U59 DLEU2 region), that encompasses the second DLEU2 promoter, we demonstrate that these CLL cells carry a mono-allelic deletion of this region, which entails loss of the primiR regulation by the DLEU2 promoter ( occupied by RPII).Table 1primiR 15a/16-1 transcritpion by RPII independent mechanism correlates with ZAP70 expression in 13q deleted CLL.SampleFISHCopy number variation (CNV)ZAP70IGVHRelative expression after α amanitin treatment (2µg/ml)primiR 15a/16-1RNA PolymeraseU59 DLEU1miR 15a/16-1primiR15a/16-1pretRNAtyrpreACTBpreGAPDHLLC3113qnd-M↓=↓IILLC42NK+/--M=↓↓IIILLC1813q+/--M↓=↓IILLC0713q+/--U↓==IILLC45NK+/--M↓=↓IILLC50NK+/--M==↓IIILLC52A13q+/--M=nd↓IIILLC6113q+/--M↓=↓IILLC8113q+/--M↓=↓IILLC4713q+/--M==↓IIILLC03ANK+/--M↓=ndIICLL4Tw13q+/--M↓=↓IICLL3TwNK+/-+M==↓IIILLC0412tri/13q+/-+/++U=↓↓IIILLC6413q+/-+U=↓↓IIILLC7013q+/++/++U==↓IIILLC3613q+/-+M=↓↓IIILLC80NK+/-+/++M==↓IIILLC17ANK+/-+/++nd=nd↓III Overall these data may clarify important genetic features of the major subgroup of CLL patients and highlight the concept that regulation of the expression of the miR-15a/16-1 is the critical event in CLL pathogenesis. Being ZAP70 high expression associated with poor prognosis in CLL, we show that the concomitant presence of different mechanisms of transcriptional regulation of miR-15a and miR-16-1 could have different impacts on the pathogenesis/progression of the CLL. nd: not determined, M: IGVH mutated, U: IGVH unmutated, CNV: Copy number variation, NK, normal karyotype; 13q, deletion of 13q chromosome region; 12tri, 12 trisomy; +/+, presence of both alleles; +/-, monoallelic deletion; -, ZAP70≤20%; +, ZAP70 〉 20%; ↓, downregulation of RNA expression after α amanitin treatment; =, no change in the RNA expression after α amanitin treatment; II, RPII; III, RPIII. Fisher's test: RPIII vs ZAP70, p:0.0128; RPIII vs IGVH, p:0.576 Disclosures: No relevant conflicts of interest to declare.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.V122.21.3753.3753
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2013
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Bookmarklink
